Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Ferris RL"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 50
Tytuł:
Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.
Autorzy:
Nayak JV
Walvekar RR
Andrade RS
Daamen N
Lai SY
Argiris A
Smith RP
Heron DE
Ferris RL
Johnson JT
Branstetter BF IV
Nayak, Jayakar V
Walvekar, Rohan R
Andrade, Regiane S
Daamen, Nicole
Lai, Stephen Y
Argiris, Athanassios
Smith, Ryan P
Heron, Dwight E
Ferris, Robert L
Pokaż więcej
Źródło:
Laryngoscope; 2007, Vol. 117 Issue 12, p2129-2134, 6p
Czasopismo naukowe
Szczegóły
Tytuł:
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
Autorzy:
Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS 'Fondazione G. Pascale', Naples, Italy. .
Avallone A; Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
Bifulco C; Translational Molecular Pathology and Molecular Genomics, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Bracarda S; Department of Oncology, Medical and Translational Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy.
Brody JD; Tisch Cancer Institute, Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Emens LA; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.; Ankyra Therapeutics, Cambridge, MA, USA.
Ferris RL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Formenti SC; Weill Cornell Medicine, New York, NY, USA.
Hamid O; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Kirchhoff T; Laura and Isaac Perlmutter Cancer Center, New York University (NYU) School of Medicine, NYU Langone Health, New York, NY, USA.
Klebanoff CA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Lesinski GB; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Monette A; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Neyns B; Department of Medical Oncology, University Hospital Brussel, Brussels, Belgium.
Odunsi K; University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
Paulos CM; Department of Surgery and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.; Translational Research for Cutaneous Malignancies, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Powell DJ Jr; Center for Cellular Immunotherapies, Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Rezvani K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Segal BH; Department of Internal Medicine and Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Singh N; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Sullivan RJ; Melanoma Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Fox BA; Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Jul 20; Vol. 21 (1), pp. 488. Date of Electronic Publication: 2023 Jul 20.
Typ publikacji:
Congress
MeSH Terms:
Melanoma*/pathology
Humans ; Immunotherapy ; Immunotherapy, Adoptive ; Italy ; Tumor Microenvironment
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors.
Autorzy:
Sander CA; UPMC Hillman Cancer Center, University of Pittsburgh, L2.19 Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA, USA.; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Rush EA; UPMC Hillman Cancer Center, University of Pittsburgh, L2.19 Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA, USA.; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Shi J; UPMC Hillman Cancer Center, University of Pittsburgh, L2.19 Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA, USA.; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Arantes LMRB; UPMC Hillman Cancer Center, University of Pittsburgh, L2.19 Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA, USA.; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.
Tesi RJ; INmune Bio, La Jolla, CA, USA.
Ross MA; Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Calderon MJ; Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Watkins SC; Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Kirkwood JM; UPMC Hillman Cancer Center, University of Pittsburgh, L2.19 Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA, USA.; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Ferris RL; UPMC Hillman Cancer Center, University of Pittsburgh, L2.19 Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA, USA.; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Butterfield LH; UPMC Hillman Cancer Center, University of Pittsburgh, L2.19 Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA, USA.; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.; School of Medicine Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Vujanovic L; UPMC Hillman Cancer Center, University of Pittsburgh, L2.19 Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA, USA. .; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. .; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2022 Jul 25; Vol. 20 (1), pp. 331. Date of Electronic Publication: 2022 Jul 25.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Melanoma*/drug therapy
Melanoma*/genetics
Melanoma*/metabolism
Receptors, Tumor Necrosis Factor, Type II*/genetics
Receptors, Tumor Necrosis Factor, Type II*/metabolism
Humans ; NF-kappa B ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins B-raf/genetics ; Receptors, Tumor Necrosis Factor, Type I/genetics ; Receptors, Tumor Necrosis Factor, Type I/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021.
Autorzy:
Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. .
Avallone A; Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
Bhardwaj N; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bifulco C; Providence Genomics and Earle A. Chiles Research Institute, Portland, OR, USA.
Bracarda S; Medical and Translational Oncology Unit, Department of Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy.
Brody JD; Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Buonaguro L; Department of Experimental Oncology, Innovative Immunological Models Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
Demaria S; Department of Radiation Oncology, Weill Cornell Medical College; Sandra and Edward Meyer Cancer Center; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Emens LA; Magee Women's Hospital/UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Ferris RL; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Galon J; INSERM, Laboratory of Integrative Cancer Immunology/Equipe Labellisée Ligue Contre Le Cancer/Centre de Recherche Des Cordeliers, Sorbonne Université, Université Paris Cité, Marseille, France.
Khleif SN; The Loop Immuno Oncology Laboratory, Georgetown University Medical School, Washington, DC, USA.
Klebanoff CA; Human Oncology and Pathogenesis Program, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center (MSKCC)/Center for Cell Engineering, MSKCC/Parker Institute for Cancer Immunotherapy/Weill Cornell Medical College, New York, NY, USA.
Laskowski T; Head of New Therapeutic Products - Personalized Medicine, Lonza Global, Houston, TX, USA.
Melero I; Department of Immunology and Immunotherapy, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain.
Paulos CM; Winship Cancer Institute at Emory University, Atlanta, GA, USA.
Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
Ruella M; Center for Cellular Immunotherapies and Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Taube JM; Department of Dermatology, Johns Hopkins University SOM, Baltimore, MD, USA.
Fox BA; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA.
Hwu P; Moffitt Cancer Center, Tampa, FL, USA.
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2022 Jun 07; Vol. 20 (1), pp. 257. Date of Electronic Publication: 2022 Jun 07.
Typ publikacji:
Journal Article
MeSH Terms:
Biomarkers, Tumor*/metabolism
Melanoma*
Humans ; Immunologic Factors ; Immunotherapy ; Italy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 50

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies